Tesaro sets terms and counts on experience to lure investors and raise $80M IPO
This article was originally published in Scrip
Executive Summary
Tesaro, a US start-up which has an aggressive growth strategy and hopes to become a notable player in oncology drug development, is counting on investors showing an interest in its initial public offering of six million shares, priced between $12 and $15 each. At a mid-range point of $13.50, it could raise $81 million.